A RCT of CenteringPregnancy on Birth Outcomes and Maternal Inflammation

Preterm Birth Clinical Trial

— PIINC  

Official title:

Psychosocial Intervention, Maternal Inflammation, and Birth Outcomes: Centering vs. Routine Prenatal Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04097548
• Other study ID #: EH17-256
• Status: Completed
• Phase: N/A
• Start date: August 8, 2018
• Est. completion date: March 31, 2023

Study information

• Verified date: November 2023
• Source: NorthShore University HealthSystem
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the PIINC study is to identify differences in placental inflammatory lesions between women participating in group prenatal care versus standard prenatal care, and additionally, examine whether the frequency of placental inflammatory lesions differ by race and income. The investigators hypothesize that women participating in group prenatal care will have lower pro-inflammatory profiles compared to women in routine prenatal care.

Description:

This is a supplementary investigation of placental inflammatory lesions among participants enrolled in a randomized controlled trial comparing biomedical, behavioral and psychosocial outcomes among pregnant women who participate in CenteringPregnancy group prenatal care, to women in the traditional individual prenatal care and to investigate whether improving women's stress, activation and engagement will explain the potential benefits of CenteringPregnancy on outcomes and health disparities. The study will be conducted in a large prenatal care center in South Carolina. Eligible White and Black women will be recruited before 20 weeks of gestational age with low risk pregnancy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1133
• Est. completion date: March 31, 2023
• Est. primary completion date: October 31, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 14 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Enrollment in NICHD 1R01HD082311: Centering and Racial Disparities: A Randomized Controlled Trial on CenteringPregnancy (the "CRaDle" trial).

2. Pregnant women aged between 14-45 years

3. Enrolled in prenatal care by 20 6/7 weeks' gestation

Exclusion Criteria:

1. Medical complications of pregnancy that would preclude prenatal care provision by nurse practitioners or participation in group care

• Pregestational diabetes,

• Severe chronic hypertension requiring medication,

• Morbid Obesity with BMI >49.99

• Renal disease with baseline proteinuria >1g/24 hours

• Any disease requiring chronic immunosuppression (SLE, solid organ transplant)

• Active pulmonary tuberculosis

• Sickle cell anemia

• Human Immunodeficiency Virus Infection

• Other medical conditions that would exclude women from group care at the discretion of the PI

2. Pregnancy complications that would preclude prenatal care provision by nurse practitioners or participation in group care

• Multiple gestation

• Lethal fetal anomalies

• Other pregnancy complications that would exclude women from group care at the discretion of the PI

3. Social and behavioral complications of pregnancy which would preclude prenatal care provision by nurse practitioners or participation in group care

• Current incarceration

• Severe psychiatric illness

Related Conditions & MeSH terms

• Inflammation
• Premature Birth
• Preterm Birth

Intervention

Behavioral:
• CenteringPregnancy
Pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.

Locations

Country	Name	City	State
United States	Greenville Health System	Greenville	South Carolina

Sponsors (4)

Lead Sponsor	Collaborator
NorthShore University HealthSystem	Northwestern University, Prisma Health-Upstate, University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of placental chronic inflammatory lesions, characterized histologically		Measured at delivery
Primary	Prevalence of placental chronic inflammatory lesions stratified by placental compartment - decidua vs. villous layer vs. membranes		Measured at delivery
Secondary	Concentration (pg/mL) of inflammatory cytokines in peripheral maternal blood via multiplex immunoassays	Circulating inflammatory biomarkers C-reactive protein, IL-6, IL-8, IL-10, IL-13, INF-a, and TNF-a (pg/mL) in maternal serum will be measured during the second trimester between 20 weeks 0 days and 25 weeks and 6 days gestation, and during the third trimester between 32 weeks 0 days and 43 weeks 0 days	Up to 43 weeks gestation
Secondary	Differential expression of mRNA gene transcripts for 34,000 human genes	Characterization of transcription control differences by exposure in maternal blood via TELiS promoter sequence analysis. Pathways involved in fetal tolerance, inflammatory activity, and organ development will be characterized. Will be measured during the second trimester between 20 weeks 0 days and 25 weeks and 6 days gestation, and during the third trimester between 32 weeks 0 days and 43 weeks 0 days. The number of differentially expressed transcripts will be totaled. Differential expression will be determined by greater than or equal to a 1.25-fold differential expression between exposure groups.	Up to 43 weeks gestation
Secondary	Differential expression of mRNA gene transcripts for 34,000 human genes	Characterization of transcription control differences by exposure in fresh placental biopsies via TELiS promoter sequence analysis. Pathways involved in fetal tolerance, inflammatory activity, and organ development will be characterized. The number of differentially expressed genes will be totaled. Differential expression will be determined by greater than or equal to a 1.25-fold differential expression between exposure groups.	Measured at delivery